/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Headquartered in Cambridge, Massachusetts, Biogen Inc. (BIIB) researches, develops, and commercializes therapies for severe neurological, immunological, and rare disorders. Commanding a market cap of approximately $28.8 billion, its portfolio spans treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and other debilitating conditions.
Over the past 52 weeks, Biogen’s shares have appreciated 41.9%, substantially outperforming the S&P 500 Index ($SPX), which delivered an 11.8% gain over the same period. Year-to-date (YTD), BIIB stock is up another 11.7%, while the broader index has recorded a marginal decline.